|
|
|
|
|
| You are here : Equity > Corporate Info > Profit & Loss |
|
|
Neuland Laboratories Ltd
|
Pharmaceuticals - Indian - Bulk Drugs
|
|
|
|
|
BSE Code :
|
524558
|
NSE Symbol :
|
NEULANDLAB
|
P/E :
|
64.51
|
|
|
|
ISIN Demat :
|
INE794A01010
|
Div & Yield % :
|
0.12
|
EPS :
|
186.59
|
|
|
|
Book Value :
|
1081.5200264
|
Market Cap( Cr.) :
|
15443.21
|
Face Value :
|
10
|
|
|
|
|
|
|
|
|
| | Mar 2024
( Cr) | Mar 2023
( Cr) | Mar 2022
( Cr) | Mar 2021
( Cr) | Mar 2020
( Cr) | | | | | | | | Sales Turnover | 1,558.58 | 1,191.20 | 951.08 | 936.91 | 762.71 | | Excise Duty | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | | Net Sales | 1,558.58 | 1,191.20 | 951.08 | 936.91 | 762.71 | | Other Income | 12.54 | 9.75 | 2.08 | 16.09 | 3.89 | | Stock Adjustments | 55.14 | 9.51 | 15.41 | 1.24 | 11.16 | | Total Income | 1,626.26 | 1,210.46 | 968.57 | 954.24 | 777.76 | | | | | | | | Raw Materials | 636.49 | 491.98 | 441.79 | 443.04 | 394.41 | | Power & Fuel Cost | 48.72 | 48.62 | 42.21 | 39.21 | 32.75 | | Employee Cost | 248.53 | 194.84 | 175.76 | 144.02 | 118.48 | | Other Manufacturing Expenses | 103.73 | 82.69 | 84.92 | 73.71 | 61.79 | | Selling & Administrative Expenses | 104.29 | 88.50 | 70.50 | 79.80 | 51.76 | | Miscellaneous Expenses | 10.04 | 22.77 | 9.12 | 11.93 | 13.21 | | Less : Pre-operative Expenses Capitalised | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | | Total Expenditure | 1,151.81 | 929.40 | 824.29 | 791.71 | 672.41 | | Operating Profit | 474.47 | 281.06 | 144.27 | 162.54 | 105.34 | | Interest | 14.00 | 13.07 | 13.49 | 17.90 | 21.57 | | Gross Profit | 460.47 | 267.99 | 130.78 | 144.64 | 83.77 | | Depreciation | 59.70 | 52.78 | 49.04 | 39.68 | 31.28 | | Profit Before Tax | 400.77 | 215.21 | 81.74 | 104.96 | 52.49 | | Tax | 99.59 | 50.39 | 20.42 | 12.48 | 0.00 | | Fringe Benefit tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | | Deferred Tax | 1.59 | 1.70 | -2.22 | 12.18 | 36.62 | | Reported Net Profit | 299.60 | 163.12 | 63.53 | 80.29 | 15.88 | | Extraordinary Items | -0.30 | -0.66 | -1.36 | 9.81 | 0.12 | | Adjusted Net Profit | 299.90 | 163.78 | 64.89 | 70.48 | 15.76 | | Adjustment below Net Profit | 0.00 | 0.00 | 0.00 | 0.00 | -0.18 | | P & L Balance brought forward | 460.54 | 303.84 | 244.15 | 166.42 | 155.67 | | Statutory Appropriations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | | Appropriations | 12.83 | 6.41 | 3.85 | 2.57 | 4.95 | | P & L Balance carried down | 747.31 | 460.54 | 303.84 | 244.15 | 166.42 | | Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | | Preference Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | | Equity Dividend % | 140.00 | 100.00 | 50.00 | 50.00 | 20.00 | | Dividend Per Share(Rs) | 14.00 | 10.00 | 5.00 | 5.00 | 2.00 | | Earnings Per Share-Unit Curr | 232.24 | 126.44 | 49.25 | 62.24 | 12.31 | | Earnings Per Share(Adj)-Unit Curr | 232.24 | 126.44 | 49.25 | 62.24 | 12.31 | | Book Value-Unit Curr | 988.88 | 765.49 | 647.06 | 605.44 | 546.26 | | Book Value(Adj)-Unit Curr | 988.88 | 765.49 | 647.06 | 605.44 | 546.26 |
|
|
|
Loading....
|
|
|